It is therefore essential to propose strategies to overcome the BBB and improve the brain kinetics of radiolabeled antibodies to enable quantitative estimation of immune biomarkers such as PD-L1 in infiltrative brain tumors like GBM using immunoPET 11. The gene discussed is CD274; the disease is glioblastoma.